latest news releases from the newsroom
Market Pulse Announces its Stocks to Watch List for Monday, April 25, 2005: TLPE, MSFT, SMTR, NT
ATLANTA, April 25, 2005 (PRIMEZONE) -- Market Pulse is pleased to introduce our featured stock, TelePlus Enterprises, Inc. (OTCBB:TLPE), to the investment community! TelePlus is new to Market Pulse and is poised to become a significant player in the wireless communications industry! TLPE has had several excellent news announcements out lately and one again before today's opening bell regarding an update on their recent acquisitions! Investors should be watching this one closely! Other notable stocks that look great lately from a fundamental and technical perspective include:
Mobile Satellite Ventures
Mobile Satellite Ventures Acquires Celsat's Patent Portfolio
RESTON, Va., April 25, 2005 (PRIMEZONE) -- Mobile Satellite Ventures (MSV) announced today that it has acquired the entire patent portfolio of one of the original developers of the hybrid satellite-terrestrial system concept, Celsat, Inc. The Celsat patents include thirteen granted, and two additional pending, patents with issue dates as early as 1991. The Celsat patents further strengthen MSV's existing ATC patent portfolio in the areas of CDMA architecture and radio resource management. These patents join MSV's extensive and rapidly growing patent portfolio, including four omnibus patents of nearly 600 allowed claims. As previously announced, after years of invention and investment, MSV's comprehensive patent portfolio is emerging from the pipeline.
Capital Research Group, Inc
Early Stock Market Alerts for Monday, April 25, 2005: CYAD, QCOM, CSCO, KLAC
WESTON, Fla., April 25, 2005 (PRIMEZONE) -- TheSUBWAY.com names the following stocks to its Stock Alerts List: CyberAds Inc. (OTCBB:CYAD), QUALCOMM Incorporated (Nasdaq:QCOM), Cisco Systems Inc. (Nasdaq:CSCO), KLA-Tencor Corporation (Nasdaq:KLAC).
Labaton Sucharow LLP
Shareholders Seek To Recover Damages from Doral Financial Corp. -- DRL
NEW YORK, April 25, 2005 (PRIMEZONE) -- The law firm of Goodkind Labaton Rudoff & Sucharow LLP has filed a class action lawsuit in the United States District Court for the Southern District of New York, on behalf of persons who purchased or otherwise acquired publicly traded securities of Doral Financial Corp. ("Doral" or the "Company") (NYSE:DRL) between January 17, 2001 and April 18, 2005, inclusive, (the "Class Period"). The lawsuit was filed against Doral, PricewaterhouseCoopers, LLP, Salomon Levis, Richard F. Bonini and Richardo Melendez ("Defendants").
New Century Companies, Inc.
New Century Announces $5,000,000 Senior Debt Facility
LOS ANGELES, April 25, 2005 (PRIMEZONE) -- New Century Companies, Inc. (the "Company") (OTCBB:NCNC) announced today it has received a signed commitment for a $5,000,000 long term senior debt facility. Terms of the agreement include 15 years' interest only with principal pay down thereafter and a minority stock ownership in New Century. This senior debt is expected to close in 60 days and subject to final due diligence by the lender. Proceeds will be utilized by the company for general working capital to build machines for inventory and to expand New Century's manufacturing capabilities in to other business segments.
Capital Research Group, Inc
TheSUBWAY.com Announces its Stock Market Standouts List for Monday, April 25, 2005: CYAD, DELL, JNPR, GOOG
WESTON, Fla., April 25, 2005 (PRIMEZONE) -- TheSUBWAY.com announces the following stocks to its Stock Market Standouts List: CyberAds Inc. (OTCBB:CYAD), Dell Inc. (Nasdaq:DELL), Juniper Networks Inc. (Nasdaq:JNPR), Google Inc. (Nasdaq:GOOG).
Biovitrum Completes Acquisition of Cambridge Biotechnology Ltd.
STOCKHOLM, Sweden, April 25, 2005 (PRIMEZONE) -- An extra annual general meeting of the shareholders in Biovitrum AB has taken the formal decisions required to complete the acquisition of Cambridge Biotechnology Ltd (CBT). As a wholly owned subsidiary of Biovitrum, CBT will be included in the Group's accounts effective April 18. CBT's drug discovery operations focus on obesity, pain and inflammation. The company's projects are at an advanced stage, with one currently in the clinical phase and another expected to enter Phase I in 2006. As a Biovitrum subsidiary, CBT will continue to operate as an autonomous and innovative R&D unit, based in Cambridge, in the UK. "The acquisition of CBT is in line with our core business-development strategy and is significant for Biovitrum. We are developing our therapeutic base and this acquisition provides us with a direct connection into one of Europe's most interesting research and biotech clusters, says Mats Pettersson," CEO of Biovitrum.